Physician profile
Werner Cadera
NPI 1649279894
$486.99
in general payments reported to CMS, 2019-2025
14 companies · $40.98 in 2025
The $40.98 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.85 · 2020: $70.49 · 2021: $18.78 · 2022: $58.30 · 2023: $46.85 · 2024: $154 · 2025: $40.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $71.46 | 2022-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $60.68 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $52.29 | 2022-2024 | Xeomin |
| Kala Pharmaceuticals, INC. | $43.65 | 2019-2021 | |
| Oyster Point Pharma, INC. | $43.41 | 2022-2024 | Ryzumvi, Tyrvaya |
| Novartis Pharmaceuticals Corporation | $42.02 | 2019-2020 | |
| Abbvie INC. | $29.80 | 2024 | |
| Carl Zeiss Meditec, INC. | $26.63 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.42 | 2019 | |
| Dompe US, INC. | $21.23 | 2025 | Oxervate |
| Merck Sharp & Dohme LLC | $21.00 | 2024 | Bridion |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Travere Therapeutics, INC. | $19.30 | 2019 | |
| Aerie Pharmaceuticals, INC. | $14.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Werner Cadera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.